Allowing NHS doctors to offer a “cheap, safe and effective” drug to treat a common eye condition could release up to A 102 million a year for other patient services but its access is being blocked by the pharmaceutical company behind it, health experts have claimed. Wet age-related macular degeneration is currently treated with Lucentis, but clinical leaders want Avastin, which is currently licensed for cancer treatment, to be given to wet AMD patients.
Are you up for a challenge?
